Interim Report January – March 2019

BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease. Phase 1-study with ABBV-0805 in the Parkinson program startedFinancial summary for the period January – March 2019 · Net revenues for the period amounted to MSEK 63.4 (52.3), which is an increase of MSEK 11.1 · Operating profit amounted to MSEK 17.3 (18.9), a decrease of MSEK 1.6. The operating margin was 27.3 percent (36.1) · Profit for the period amounted to MSEK 13.6 (15.4) and earnings per share1were SEK 0.15 (0.18) · Cash flow from operating activities amounted to MSEK 333.6 (-42.0)